Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  conditioning
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
EN
The purpose of this study was to examine the acute effect of upper body complex training on power output, as well as to determine the requisite preload intensity and intra-complex recovery interval needed to induce power output increases. Nine amateur-level combat/martial art athletes completed four distinct experimental protocols, which consisted of 5 bench press repetitions at either: 65% of one-repetition maximum (1RM) with a 4 min rest interval; 65% of 1RM with an 8 min rest; 85% of 1RM with a 4 min rest; or 85% of 1RM with an 8 min rest interval, performed on different days. Before (pre-conditioning) and after (post-conditioning) each experimental protocol, three bench press throws at 30% of 1RM were performed. Significant differences in power output pre-post conditioning were observed across all experimental protocols (F=26.489, partial eta2=0.768, p=0.001). Mean power output significantly increased when the preload stimulus of 65% 1RM was matched with 4 min of rest (p=0.001), and when the 85% 1RM preload stimulus was matched with 8 min of rest (p=0.001). Moreover, a statistically significant difference in power output was observed between the four conditioning protocols (F= 21.101, partial eta²=0.913, p=0.001). It was concluded that, in complex training, matching a heavy preload stimulus with a longer rest interval, and a lighter preload stimulus with a shorter rest interval is important for athletes wishing to increase their power production before training or competition.
2
Content available remote

A Review on the Effects of Soccer Small-Sided Games

75%
EN
Over the last years there has been a substantial growth in research related to specific training methods in soccer with a strong emphasis on the effects of small-sided games. The increase of research in this topic is coincident with the increase of popularity obtained by specific soccer conditioning, which involves training players to deal with soccer match situations. Given the limited time available for fitness training in soccer, the effectiveness of small-sided games as a conditioning stimulus needs to be optimized to allow players to compete at the highest level. Available studies indicate that physiological responses (e.g. heart rate, blood lactate concentration and rating of perceived exertion), tactical and technical skill requirements can be modified during small-sided games by altering factors such as the number of players, the size of the pitch, the rules of the game, and coach encouragement. However, because of the lack of consistency in small-sided games design, player fitness, age, ability, level of coach encouragement, and playing rules in each of these studies, it is difficult to make accurate conclusions on the influence of each of these factors separately.
EN
Low-grade lymphomas pose a considerable therapeutic problem, as they yield to treatment very reluctantly. Not infrequently we are faced with resistance to chemotherapy. This type of lymphomas are usually seen in persons of middle or advanced age, rarely in people under 30. Due to the presence of CD20+ receptor on cell membranes of lymphoma originating from B-cells, monoclonal antibody anti-CD20+ (rituximab) has been introduced to the therapy. This has certainly resulted in improved outcomes. Of value in consolidation treatment of low-grade lymphomas is also autologous or allogenic hematopoietic cell transplantation (autoHSCT, alloHSCT). As escalation of dose of cytostatics as myeloablative treatment prior to autoHSCT or alloHSCT may not guarantee total eradication of residual lymphoma cells, research focuses on treatment modalities which might improve late outcomes in this tumor type. In this setting useful proved radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin). Zevalin combined with high-dose chemotherapy can be used now as a component of myeloablative treatment prior to autoHSCT. Reduced intensity conditioning (RIC) contributes to reduced mortality associated with standard conditioning protocol administered prior to transplantation, but may facilitate disease recurrence. Radioimmunotherapy using ibritumomab may reduce recurrence rate and, as a conditioning measure, may be initiated on the outpatient setting, prior to admission to bone marrow transplantation center. Labeling of antibodies and their application must take place at a Nuclear Medicine Unit, observing all necessary precautions and regulations concerning radiation protection. Administration of ibritumomab is preceded by application of two doses of rituximab: 250 mg/m2, 7 days and 4 hours prior to the RIT procedure. The dose of rituximab administered one week before, according to recommended protocol of ibritumomab use, initially preceded dosimetry (administration of indium-labeled antibodies).
PL
Chłoniaki o niskim stopniu złośliwości stanowią istotny problem terapeutyczny, gdyż bardzo trudno poddają się leczeniu. Nierzadko spotykamy się z opornością na chemioterapię. Zazwyczaj chłoniaki tego typu występują u ludzi w średnim lub starszym wieku. Rzadziej u chorych młodszych (poniżej 30. roku życia). W związku z obecnością ekspresji receptora CD20+ na błonach komórkowych komórek chłoniaka wywodzącego się z komórek B zaczęto stosować poza chemioterapią przeciwciało monoklonalne antyCD20+ (rytuksymab). Oczywiście udało się dzięki temu przeciwciału poprawić efekty terapeutyczne. Swoją wartość w leczeniu konsolidującym chłoniaków o niskim stopniu złośliwości ma też przeszczepienie autologicznych bądź alogenicznych komórek krwiotwórczych (autoHSCT i alloHSCT). Ponieważ eskalacja dawek cytostatyków jako leczenie mieloablacyjne przed autoHSCT i alloHSCT może nie zapewniać pełnej eradykacji resztkowych komórek chłoniaka, poszukuje się metod terapeutycznych, które poprawiłyby odległe efekty leczenia tego typu nowotworów. Tutaj swoje miejsce znalazła radioimmunoterapia za pomocą 90Y-ibrytumomabu tiuksetanu (Zevalin). Zevalin wraz z wysokodawkową chemioterapią można obecnie stosować jako jeden ze składników leczenia mieloablacyjnego przed autoHSCT. Kondycjonowanie o zredukowanej intensywności (RIC) zmniejsza śmiertelność związaną ze schematem przygotowawczym stosowanym przed podaniem przeszczepu, ale mogą zdarzać się nawroty choroby. Radioimmunoterapia z zastosowaniem ibrytumomabu jest procedurą, która może zmniejszyć częstość nawrotów choroby i może być jako kondycjonowanie rozpoczynana ambulatoryjnie, zanim chory zostanie przyjęty do ośrodka przeszczepiania szpiku. Samo przygotowanie (znakowanie) przeciwciał i ich podanie musi się odbyć w Zakładzie Medycyny Nuklearnej, z zachowaniem niezbędnych środków ochrony radiologicznej. Podanie ibrytumomabu poprzedza infuzja dwóch dawek rytuksymabu: 250 mg/m2, 7 dni i 4 godziny przed samą procedurą RIT. Dawka rytuksymabu podana tydzień wcześniej, zgodnie z zalecanym schematem podania ibrytumomabu, pierwotnie poprzedzała dozymetrię (podanie przeciwciała znakowanego indem).
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.